Elon Musk’s neuro-implant startup Neuralink is getting ready to initiate a first-of-its-kind trial that will enable individuals who have lost the ability to talk to communicate verbally through their minds. Beginning in October, the research will convert text from the signals of the brain without the use of keyboards and standard assistive equipment.
Dongjin “D.J.” Seo, president of Neuralink, revealed the plan for a future trial in a presentation this week at the Korea Advanced Institute of Science and Technology in Seoul. The lofty project looks at individuals who have become unable to verbalize because of illness, and it would give these individuals a direct form of brain-to-voice communications.
“If you’re considering saying something, we would be recording that,” detailed Seo, outlining for the crowd the real-life application of the technology. It’s a major advance in brain-computer interface technology, and potentially, it will revolutionize the way speech-impaired individuals interact with the world outside of them.
The device operates through the detection of speech intent neural signals. When an individual thinks of saying words or phrases, their mind generates certain electric patterns. The implantable brain chip of Neuralink might be able to detect these signals and interpret them and convert the individual’s speech intent into readable text or vocal speech.
Advancing Neuralink: From Breakthrough Designation to Human Trials and Beyond
This advance is accompanied by significant regulatory support. The United States Food and Drug Administration has issued a Breakthrough Device designation to Neuralink’s device for speech indications only. It is a special approval meant to accelerate the development, evaluation, and approval of medical devices which would achieve major improvements over current therapies for life-threatening or irreversibly disabling conditions.
It has not been smooth sailing either so far. Human trials of Neuralink only commenced in 2024, after spending significant time addressing safety issues posed by the FDA. The authority had rejected the application of the company back in 2022, demanding more safety data and improvements of the device and procedures.
Since commencing human trials, Neuralink has been progressing slowly but surely. It recently disclosed that 12 people worldwide have been granted its implantable brain chip. Its early adopter users, in aggregate, have garnered over 15,000 usage hours and provided valuable insights into the device’s practicability and safety profile under real-life conditions.
The advantages of the technology would extend far beyond speech restoration. People who have lost speech due to diseases of the speech area of the brain, including ALS (Lou Gehrig’s disease), stroke, spinal cord injuries, or other neurological disorders might be restored to a rudimentary form of human expression. Most of those afflicted with speech disorders rely on eye-tracking computers, special keyboards, or other adaptive technologies, which are slow and laborious to use.
The Dawn of Thought-to-Speech, Neuralink’s New Frontier
What’s especially exciting about the approach of Neuralink is its speed and naturalness potential. Most standard assistive communication devices involve users painfully choosing letters or words, so conversations end up being slow and halting. Brain-to-text technology potentially enables something at the speed of thought, so communications might become smoother and more natural.
But there are concerns over whether the technology will be available and safe in the long term. Brain implantation is a highly invasive form of treatment, and there are built-in risks involved; the long-term consequences of having computer chips in the head remain in research stages. Also, the expensive technology might only become available for a few patients at first.
The October proceedings would be of particular interest for the medical fraternity, speech-impaired patients, and technology enthusiasts equally. If it succeeds, this application will pave the way for broader usage of the brain-computer interface technology, which would help paralyzed patients, depressive patients, and those suffering from neurological disorders.
While Neuralink would not immediately confirm and respond to questions for further details of the trial, the news is a significant milestone in the company’s endeavors toward the creation of a computer-brain bridge. Using this technology, possibilities for regained speech and regained autonomy are held out for the millions of speech-impaired individuals worldwide.
This trial’s outcomes may bring the technology of converting the brain into speech from experimental treatment use into standard medical practice, and by so doing, revolutionize lives nationwide.
